BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has appointed Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Bermudes, with over 20 years of experience in brain stimulation therapies, is considered a preeminent clinician in the TMS field. He replaces Dr. Aron Tendler, who will continue collaborating on strategic research projects.
Dr. Bermudes brings extensive experience as a practicing physician, researcher, and entrepreneur. He co-founded a behavioral health care network with 24 outpatient clinics, pioneered new therapies, and launched successful telehealth programs. He is also an Associate Physician at UC Davis Department of Psychiatry and Behavioral Sciences and the lead editor of a renowned book on Transcranial Magnetic Stimulation.
BrainsWay (NASDAQ & TASE: BWAY), leader nei trattamenti di neurostimolazione non invasiva per disturbi della salute mentale, ha nominato Richard A. Bermudes, M.D. come Chief Medical Officer (CMO), con effetto dal 1 settembre 2024. Il Dr. Bermudes, con oltre 20 anni di esperienza nelle terapie di stimolazione cerebrale, è considerato un clinico di riferimento nel campo della TMS. Sostituisce il Dr. Aron Tendler, che continuerà a collaborare a progetti di ricerca strategici.
Il Dr. Bermudes porta con sé una vasta esperienza come medico praticante, ricercatore e imprenditore. Ha co-fondato una rete di assistenza sanitaria comportamentale con 24 cliniche ambulatoriali, ha innovato nuove terapie e ha avviato programmi di telemedicina di successo. È anche un medico associato presso il Dipartimento di Psichiatria e Scienze Comportamentali dell'UC Davis ed è il principale curatore di un libro rinomato sulla Stimolazione Magnetica Transcranica.
BrainsWay (NASDAQ & TASE: BWAY), líder en tratamientos de neuroestimulación no invasivos para trastornos de salud mental, ha nombrado a Richard A. Bermudes, M.D. como Director Médico (CMO), con efecto a partir del 1 de septiembre de 2024. El Dr. Bermudes, con más de 20 años de experiencia en terapias de estimulación cerebral, es considerado un clínico destacado en el campo de la TMS. Sustituye al Dr. Aron Tendler, quien seguirá colaborando en proyectos de investigación estratégica.
El Dr. Bermudes aporta una amplia experiencia como médico en ejercicio, investigador y empresario. Co-fundó una red de atención de salud conductual con 24 clínicas ambulatorias, pionero en nuevas terapias y lanzó programas exitosos de telemedicina. También es médico asociado en el Departamento de Psiquiatría y Ciencias del Comportamiento de UC Davis y el editor principal de un libro reconocido sobre Estimulación Magnética Transcraneal.
BrainsWay (NASDAQ & TASE: BWAY)는 정신 건강 장애를 위한 비침습적 신경 자극 치료의 선두주자로서 리차드 A. 베르무데스, M.D.를 최고 의료 책임자(CMO)로 임명했습니다. 임기는 2024년 9월 1일부터 시작됩니다. 베르무데스 박사는 20년 이상의 뇌 자극 치료 경험을 보유하고 있으며, TMS 분야의 저명한 임상의로 알려져 있습니다. 그는 전략적 연구 프로젝트에서 계속 협력할 아론 텐들러 박사를 대체합니다.
베르무데스 박사는 임상 의사, 연구자 및 기업가로서 광범위한 경험을 제공합니다. 그는 24개의 외래 진료소를 가진 행동 건강 관리 네트워크를 공동 설립하고, 새로운 치료법을 개척하며, 성공적인 원격 의료 프로그램을 론칭했습니다. 그는 또한 UC 데이비스 정신과 및 행동 과학과의 부교수이며, 경두개 자기 자극에 관한 유명한 책의 편집 주임입니다.
BrainsWay (NASDAQ & TASE: BWAY), un leader dans les traitements de neurostimulation non invasive pour les troubles de la santé mentale, a nommé Richard A. Bermudes, M.D. comme Directeur Médical (CMO), avec effet au 1er septembre 2024. Le Dr Bermudes, fort de plus de 20 ans d'expérience dans les thérapies de stimulation cérébrale, est considéré comme un clinicien éminent dans le domaine de la TMS. Il remplace le Dr Aron Tendler, qui continuera à collaborer à des projets de recherche stratégique.
Le Dr Bermudes apporte une expérience approfondie en tant que médecin praticien, chercheur et entrepreneur. Il a cofondé un réseau de soins de santé comportementale avec 24 cliniques ambulatoires, a été pionnier dans de nouvelles thérapies et a lancé des programmes de télémédecine réussis. Il est également médecin associé au Département de psychiatrie et des sciences du comportement de l'UC Davis et rédacteur en chef d'un livre renommé sur la stimulation magnétique transcrânienne.
BrainsWay (NASDAQ & TASE: BWAY), führend in nicht-invasiven Neurostimulationsbehandlungen für psychische Erkrankungen, hat Richard A. Bermudes, M.D. als Chief Medical Officer (CMO) ernannt, der am 1. September 2024 wirksam wird. Dr. Bermudes, der über 20 Jahre Erfahrung in der Gehirnstimulationstherapie verfügt, gilt als führender Kliniker im Bereich TMS. Er tritt die Nachfolge von Dr. Aron Tendler an, der weiterhin an strategischen Forschungsprojekten mitwirken wird.
Dr. Bermudes bringt umfangreiche Erfahrung als praktizierender Arzt, Forscher und Unternehmer mit. Er co-gründete ein Netzwerk für Verhaltensgesundheitsversorgung mit 24 ambulanten Kliniken, entwickelte neue Therapien und startete erfolgreiche Telemedizinprogramme. Außerdem ist er assoziierter Arzt an der UC Davis Abteilung für Psychiatrie und Verhaltenswissenschaften und der Hauptredakteur eines renommierten Buches über transkranielle Magnetstimulation.
- Appointment of a highly experienced and respected clinician as CMO
- Dr. Bermudes brings 20+ years of experience in brain stimulation therapies
- New CMO has entrepreneurial experience in founding a behavioral health care network
- Continued collaboration with former CMO on strategic research projects
- None.
Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field
BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects.
“We are excited to have Richard join our team to lead and shape BrainsWay’s clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing physician for over 20 years, combined with his research experience and entrepreneurial spirit, make him extremely well-positioned for the role,” said Hadar Levy, BrainsWay’s Chief Executive Officer. “We appreciate Dr. Tendler’s significant contributions to the Company over the past decade, and greatly appreciate that he has agreed to collaborate with the BrainsWay team on important strategic research projects.”
With more than 20 years of experience pioneering new brain stimulation and innovative mental health technologies, Dr. Bermudes is widely considered one of the preeminent clinicians in the TMS field. Having co-founded an innovative behavioral health care network with 24 outpatient clinics, pioneered in the adoption of new therapies across the treatment landscape, and launched successful telehealth programs, he has been at the forefront of improving mental health through innovative care. Dr. Bermudes is also an Associate Physician at the UC Davis Department of Psychiatry and Behavioral Sciences, and his academic contributions include serving as a Diplomat of the Academy of Cognitive Therapy. He is the lead editor of the widely acclaimed book, “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice,” and holds an M.D. from the University of California, San Diego, School of Medicine.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
FAQ
Who is the new Chief Medical Officer of BrainsWay (BWAY)?
What experience does Dr. Richard A. Bermudes bring to BrainsWay (BWAY)?
When does Dr. Richard A. Bermudes start as CMO of BrainsWay (BWAY)?
What will happen to BrainsWay's (BWAY) former CMO, Dr. Aron Tendler?
